drugset / Trial / NCT05363670

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

NCT05363670

Phase 2 Completed 18 enrolled ARS Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.

Timeline

Start
2022-07-28
Primary completion
2024-02-02
Completion
2024-02-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARS-1 Unknown 1 mg Intranasal
Comparator ARS-1 Unknown 2 mg Intranasal
Comparator Salbutamol Unknown 180 ug Inhaled

Indications